Nanobiotix Shares Set a New Record at €41.52, Up 1,202% Over the Year
The French biotech company reaches a new all-time high of €41.52 during the session, surpassing the previous peak of €40.52. The stock is trading at €40.16 at midday, up 8.83% from the last close. Nanobiotix ranks as the second highest gainer on the SBF 120, in an index that is otherwise down by 0.85%.
Second Highest Rise on the SBF 120 in a Downward Trending Paris Market
Nanobiotix stands out at midday with an 8.83% gain at €40.16. The stock takes the second spot in terms of gains on the SBF 120, behind Valneva (+10.83%), while the broader index falls by 0.85% and the CAC 40 drops by 0.96%. The biotech continues its spectacular trajectory: nearly 40% gained over the week, more than 92% over three months, and a return of 1,202% over the year. The session extends the acceleration that began in early May, following the FDA's green light on the amendment to the NANORAY-312 Phase 3 study protocol, announced on May 5. The previous historical record of €40.52 was reached during the session on May 7. The new peak of €41.52 reached today surpasses it by nearly one euro.
Stock Significantly Deviates from Its Moving Averages, Stretched RSI
The technical setup reflects the intensity of the movement. The price is 38.6% above the 20-day moving average (€28.97) and 116.8% above the 200-day moving average (€18.52), a gap that indicates the magnitude of the recent revaluation. The stock also trades above the upper Bollinger band (€35.19), signaling an overbought momentum. The RSI at 73 confirms this tension. No immediate releases are expected according to the available financial calendar. Today's resistance is identified at the intraday record level of €41.52.
